Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

ClinicalTrials.gov ID: NCT04645953

Public ClinicalTrials.gov record NCT04645953. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.

Study identification

NCT ID
NCT04645953
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
150 participants

Conditions and interventions

Interventions

Combination Product

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 5, 2021 (Actual)
Primary completion
Jul 26, 2022 (Actual)
Completion
Jul 26, 2022 (Actual)
Last update posted
Jun 11, 2025

2021 – 2022

United States locations

U.S. sites
18
U.S. states
12
U.S. cities
17
Facility City State ZIP Site status
Om Research Lancaster California 93535 —
Axis Clinical Trials Los Angeles California 90036 —
Precision Research Institute, LLC San Diego California 92114 —
University of South Florida Tampa Florida 33606 —
Summit Clinical Studies Athens Georgia 30607 —
Infinite Clinical Trials Morrow Georgia 30260 —
Kansas University Medical Center Kansas City Kansas 66160 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Henry Ford Health System Detroit Michigan 48202 —
Mayo Clinic Rochester Minnesota 55905 —
NY Scientific Brooklyn New York 11235 —
Temple University Hospital Philadelphia Pennsylvania 19140 —
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213 —
New Phase Research & Development, LLC Knoxville Tennessee 37909 —
Baylor College of Medicine Houston Texas 77030 —
Pioneer Research Solutions Houston Texas 77099 —
Sante Clinical Research Kerrville Texas 78028 —
Medical College of Wisconsin Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04645953, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 11, 2025 · Synced Oct 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04645953 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →